惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

罗磊的独立博客
大猫的无限游戏
大猫的无限游戏
WordPress大学
WordPress大学
酷 壳 – CoolShell
酷 壳 – CoolShell
T
Tailwind CSS Blog
Engineering at Meta
Engineering at Meta
MongoDB | Blog
MongoDB | Blog
爱范儿
爱范儿
小众软件
小众软件
MyScale Blog
MyScale Blog
美团技术团队
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
S
SegmentFault 最新的问题
G
Google Developers Blog
Stack Overflow Blog
Stack Overflow Blog
V
V2EX
量子位
云风的 BLOG
云风的 BLOG
A
About on SuperTechFans
阮一峰的网络日志
阮一峰的网络日志
Last Week in AI
Last Week in AI
Martin Fowler
Martin Fowler
C
Check Point Blog
月光博客
月光博客

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
DexCom, Inc. (DXCM) Analyst/Investor Day Transcript
2026-05-15 · via All Articles on Seeking Alpha

DexCom, Inc. (DXCM) Analyst/Investor Day May 14, 2026 4:15 PM EDT

Company Participants

Jacob Leach - President, CEO & Director
Jon Coleman - Executive VP & Chief Commercial Officer
Jereme Sylvain - Executive VP, CFO & Chief Accounting Officer
Sean Christensen - Vice President of Finance and Investor Relations

Conference Call Participants

David Roman - Goldman Sachs Group, Inc., Research Division
Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division
Larry Biegelsen - Wells Fargo Securities, LLC, Research Division
Joanne Wuensch - Citigroup Inc., Research Division
Christopher Pasquale - Nephron Research LLC
Matthew O'Brien - Piper Sandler & Co., Research Division
Richard Newitter - Truist Securities, Inc., Research Division
Joshua Jennings - TD Cowen, Research Division
Shagun Singh Chadha - RBC Capital Markets, Research Division

Presentation

Operator

Welcome to the 2026 Dexcom Investor Day. As a reminder, this presentation contains forward-looking statements. Please note our safe harbor statement included here as well as our filings with the Securities and Exchange Commission.

[Presentation]

Operator

Please welcome President and Chief Executive Officer, Jake Leach.

Jacob Leach
President, CEO & Director

Hello, everybody, and welcome to Dexcom's 2026 Investor Day. It's great to see all of you here. Thank you so much for joining us. I'm Jake Leach, President and CEO. And today, we will review our priorities that are designed to drive the next phase of growth for Dexcom. There's many things that make Dexcom extraordinary, but one that really stands out to me is our ability to imagine and build a prosperous future while simultaneously impacting the lives of millions of people every day, helping improve their diabetes management. And at the same time, we're lowering the overall cost of care for this population. There are 3 key drivers that are going to define the next phase of Dexcom's journey. First, we have an advanced product portfolio that is focused on meeting valuable, distinct, highly important things for our customers. Second, the clinical and economic value we